ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock
Key stats
- Market cap
- $177.81M
- Price / Earnings ratio
- -2.9x
- EPS (TTM)
- -$0.44
- Volume
- Loading
- 52-week high
- $2.49
- 52-week low
- $1.20
Source: third-party data provider, as of November 13, 2026
Compare with PRQR
Recent news

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
PRQR

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
PRQR

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
PRQR

ProQR's stock jumps on expanded RNA deal with Lilly
ProQR's stock jumps on expanded RNA deal with Lilly
PRQR
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 36.73
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.09
- MACD histogram
- 0.01
- SMA 50
- $1.60
- Price below SMA 50
- EMA 50
- $1.54
- Price below EMA 50
- SMA 200
- $1.68
- Price below SMA 200
- EMA 200
- $1.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
PRQR

Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
PRQR

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
PRQR

ProQR's stock jumps on expanded RNA deal with Lilly
ProQR's stock jumps on expanded RNA deal with Lilly
PRQR
News tone: automated (AI) classification of the article's content, not a price prediction.
About ProQR Therapeutics N.V. Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Anton de Boer | Founder, CEO & Executive Director | 1983 |
| Mr. Dennis Hom | Chief Financial Officer | 1975 |
| Dr. Gerard Platenburg Ph.D. | Co-Founder, Chief Scientific Officer & Executive Director | 1964 |
| Ms. Sheila Sponselee | Chief People & Operations Officer | 1984 |
| Ms. Sarah Cue Kiely | Vice President of Investor Relations & Corporate Communications | — |
| Dr. Cristina Lopez Lopez M.D., Ph.D. | Chief Medical Officer | 1976 |
| Mr. Christopher Hart Ph.D. | Chief Data & AI Officer | — |
| Dr. Golnar Karimian | Head of Hepatology | — |
| Ms. Sandra van der Kolk | Junior Financial Controller | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 36.73
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.09
- MACD histogram
- 0.01
- SMA 50
- $1.60
- Price below SMA 50
- EMA 50
- $1.54
- Price below EMA 50
- SMA 200
- $1.68
- Price below SMA 200
- EMA 200
- $1.70
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $3.00
- Average
- $6.33
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.0 | +19.0 | ||||||||||
| 2022 | -32.5 | -81.6 | -10.8 | -23.3 | -5.7 | +5.4 | +6.3 | -4.8 | -5.1 | +16.3 | +29.5 | +203.3 |
| 2023 | -19.1 | +3.5 | -27.8 | -3.1 | -23.0 | -12.4 | -8.0 | +0.0 | -18.2 | -8.0 | +33.6 | +14.5 |
| 2024 | +4.3 | -6.9 | +15.7 | -11.4 | -2.5 | -16.2 | +17.0 | +11.0 | -5.2 | +98.9 | +2.9 | -29.0 |
| 2025 | -22.6 | +3.6 | -37.6 | +28.7 | -3.5 | +14.6 | +4.5 | +8.2 | -7.0 | +27.3 | -9.7 | -4.7 |
| 2026 | -18.6 | +2.6 | +2.5 | -8.2 | +1.9 | +31.0 | -1.7 | +24.6 | -21.7 | -14.7 | -4.5 |



